Biotinylated Human LY6G6D Protein, Active
Beta LifeScience
SKU/CAT #: BLK-00159P-100UG

Biotinylated Human LY6G6D on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Biotinylated Human LY6G6D Protein, Active
Beta LifeScience
SKU/CAT #: BLK-00159P-100UG
Collections: High-quality recombinant proteins, Other recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Biotinylated Human LY6G6D Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus.It contains Asn20-Ser104. |
Purity | > 95% as determined by Tris-Bis PAGE |
Accession | O95868 |
Target Symbol | LY6G6D |
Species | Human |
Expression System | HEK293 |
Tag | C-His-Avi |
Expression Range | Asn20-Ser104 |
Mol. Weight | The protein has a predicted MW of 12.79 kDa. Due to glycosylation, the protein migrates to 15-20 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Biotinylated Human LY6G6D, His-Avi Tag at 0.5ug/ml (100ul/well) on the streptavidin precoated plate (5ug/ml). Dose response curve for Anti-LY6G6D Antibody, hFc Tag with the EC50 of 4.4ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager.LY6G6D was identified as a selectively expressed CRC antigen that can be utilized to potently re-direct and activate cytotoxic T-cells to lyse LY6G6D expressing CRC using a TcE. This effect can be spread to target negative neighboring tumor cells, potentially leading to improved therapeutic efficacy. |